Context Therapeutics Inc.

NASDAQ:CNTX

Biotechnology

Healthcare
$0.69 +2.93%

+$0.02 today

Market cap
$63.67M
Beta
1.61
P/E (TTM)
-1.5
EPS (TTM)
-$0.42
52W Low $0.56High $3.62

Volume 1.71M

Average 1.16M

CNTX Long-term Debt

Borrowings due after more than one year.

Context Therapeutics Inc.NASDAQ: CNTX

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt rises 48.1% from a year ago

Long-term debt stood at $122.37K at the end of Q1 FY2026, up 48.1% from a year earlier.

Context

  • Long-term debt amounted to 0.2% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
  • Long-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps rising in the next quarterly balance sheet after a +48.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$122.37K— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$82.61K+48.1% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.1%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Long-term Debt vs competitors

How CNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +48.1% is the highest of 2, against a peer median of +26.5%.
  • Long-term debt amounts to 0.2% of total assets for CNTX, versus a peer median of 0.0%.
CNTX Competitors
Long-term Debt for CNTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MGNXMacroGenics, Inc.Mar 2026$31.3M USD——14.4%
CLNNClene Inc.Mar 2026$16.34M USD+26.5%-11.1%75.4%
IMAImageneBio IncMar 2026$5.73M USD——4.2%
STTKShattuck Labs, Inc.Mar 2026$2.04M USD——2.0%
CNTXContext Therapeutics Inc.Mar 2026$122.37K USD+48.1%—0.2%
OVIDOvid Therapeutics Inc.Mar 2026$0 USD——0.0%
WHWKWhitehawk Therapeutics IncMar 2026$0 USD——0.0%
ORMPOramed Pharmaceuticals Inc.Mar 2026$0 USD——0.0%
CNTBConnect Biopharma Holdings LimitedDec 2025$0 USD——0.0%
IFRXInflaRx N.V.Mar 2026€0 EUR——0.0%
KLRSKalaris Therapeutics IncMar 2026$0 USD——0.0%
Peer median (excluding CNTX) —+26.5%-11.1%0.0%

Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents49.64M35.5M14.45M94.43M66M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets(0)2.36M1.6M3.47M2.36M
Total Current Assets51.26M37.85M16.05M97.9M68.35M
Property, Plant & Equipment (Net)079.54K15.52K230.78K140.07K
Goodwill00000
Intangible Assets00000
Long-term Investments50.39K0000
Tax Assets00000
Other Non-current Assets032.75K000
Total Non-current Assets50.39K112.29K15.52K230.78K140.07K
Total Assets51.31M37.97M16.06M98.13M68.49M
Account Payables1.83M936.33K2.38M1.45M2.53M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities85.53K853.51K661.3K941.7K1.42M
Total Current Liabilities3.03M3.21M4.19M2.75M8.02M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities000112.06K0
Total Liabilities3.03M3.21M4.19M2.86M8.02M
Common Stock15.97K15.97K15.97K89.7K91.88K
Retained Earnings(29.25M)(44.09M)(68.05M)(94.78M)(130.9M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity48.27M34.76M11.87M95.27M60.47M
Total Debt055.08K0219.38K112.06K
Net Debt(49.64M)(35.44M)(14.45M)(94.21M)(65.88M)

Context Therapeutics Inc.

NASDAQ:CNTX

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.